Nalaganje...
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
New, effective therapies are needed for pancreatic ductal adenocarcinoma. Ipilimumab can mediate an immunologic tumor regression in other histologies. This phase II trial evaluated the efficacy of Ipilimumab for advanced pancreatic cancer. Subjects were adults with locally advanced or metastatic pan...
Shranjeno v:
| izdano v: | J Immunother |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2010
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7322622/ https://ncbi.nlm.nih.gov/pubmed/20842054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e3181eec14c |
| Oznake: |
Označite
Brez oznak, prvi označite!
|